Experimental antibody aims to quiet spinal inflammation without X-Ray damage
NCT ID NCT05242588
First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time
Summary
This phase 2 trial tests an experimental drug called JS005 in Chinese adults with active non-radiographic axial spondyloarthritis, a form of inflammatory back pain that does not yet show damage on X-rays. Participants receive either a low, medium, or high dose of JS005 or a placebo as a series of injections over 16 weeks. The study measures how well the drug reduces symptoms and inflammation, and checks for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental anti-IL-17A monoclonal antibody called JS005
- What this could lead to
- If successful, JS005 could offer a new treatment option for people with non-radiographic axial spondyloarthritis, reducing pain and inflammation.
- What could go wrong
- This is an early phase 2 trial with only 23 participants, so results may not apply to everyone. The drug may not work better than placebo or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Anhui Provincial Hospital
Hefei, Anhui, 230001, China
-
First Affiliated Hospital of Kunming Medical University
Kunming, Yunnan, 250063, China
-
First Affiliated Hospital of Shanxi Medical University
Taiyuan, Shanxi, 650032, China
-
Nanfang Hospital of Nanfang Medical University
Guangzhou, Guangdong, 510515, China
-
North Sichuan Medical College Affiliated Hospital
Nanchong, Sichuan, 637000, China
-
People's Hospital of Xinjiang Uygur Autonomous Region
Ürümqi, Xinjiang, 8300001, China
-
Pking University Shenzhen Hospital
Shenzhen, Guangdong, 518036, China
-
Qilu Hospital of Shandong University
Jinan, Shandong, 030001, China
-
Shanghai Changzheng Hospital
Shanghai, Shanghai Municipality, 200003, China
-
Shantou University Medical Collge No.1 Affiliated Hospital
Shantou, Guangdong, 515041, China
-
Shengjing Hospital of China medical University
Shenyang, Liaoning, 110004, China
-
Shenzhen People's Hospital
Shenzhen, Guangdong, 518001, China
-
Sun Yat-sen Memorial Sun Yat-sen University
Guangzhou, Guangdong, 510120, China
-
The Affilated Hospital of Inner Mongdlia Medical University
Hohhot, Inner Mongolia, 100000, China
-
The First Affiliated Hospital of China Medical University
Shenyang, Liaoning, 110001, China
-
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, 410011, China
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, 361001, China
-
The First Hospital of Jilin University
Changchun, Jilin, 130021, China
-
The Second Affiliated Hospital of Dalian Medical University
Dalian, Liaoning, 116023, China
-
The Second Affiliated Hospital of Zhejiang University,School of Medicine
Hangzhou, Zhejiang, 450052, China
-
The Second Xiangya Hospital of Central South University
Changsha, Hunan, 410013, China
-
The Third Xiangya Hospital of Central South University
Changsha, Hunan, 361001, China
-
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, 300041, China
-
Tongji Hospital,Tongji Medical College of HUST
Wuhan, Hubei, 430030, China
-
West China Hospital, Sichuan University
Chengdu, Sichuan, 600041, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.